Our Leadership Team

John McAdam is the Chairman of Convatec Group plc. John was the Chair of United Utilities Group plc between 2008 and 2019 and served as Senior Independent Director of Cobham plc. John has previously been a Non-Executive Director of Wilmcote Holdings plc and of a number of FTSE 100 and US companies, including Rolls-Royce Group plc, J Sainsbury plc and The Sara Lee Corporation. He spent more than two decades at Unilever before joining ICI, where he became Chief Executive in 2003 until its takeover by Akzo Nobel in 2008. Previously, John was Chairman of Rentokil Initial plc from 2008; he stepped down from this role earlier in 2019. With 20 years' service as a board director, including as Chairman and Chief Executive Officer in companies undertaking transformation, John has a wealth of experience on which to draw in his role as Chairman and leader of the Board. John has a BSc (Hons) Chemical Physics, a Diploma in Advanced Studies in Science and a PhD.

Jonny Mason was appointed Chief Executive Officer on 6 November 2025, following a period as Interim CEO since 4 August 2025. Jonny joined Convatec on 31 January 2022 and was appointed CFO from 12 March 2022 when he joined the Board of Directors. Jonny has played an instrumental role in leading the company’s pivot to sustainable and profitable growth and shaping its ongoing strategy.

An engineer and accountant by training, Jonny is a seasoned C-Suite leader with an extensive track record in listed and international businesses and brings diverse strategic enterprise transformation and operational leadership experience, combined with deep financial acumen and strong customer orientation.

A talented people-leader, he has made a significant contribution to Convatec’s turnaround and pivot to sustainable and profitable growth. He has a strong track record in publicly listed and international businesses, particularly those going through transformation, where he has built and led high performing teams, shaped engaging and impactful strategy, and delivered a stronger balance sheet with a sharp focus on cash and cost control.

Prior to joining Convatec, Jonny was Chief Financial Officer of Dixons Carphone Plc, now known as Currys Plc, between 2018-2021. Previous roles include CFO of Halfords Plc from 2015 and he was their interim Chief Executive Officer between September 2017 and January 2018. Jonny has built up a diverse and strong portfolio of experience, including being CFO of Scandi Standard AB, CFO at Odeon and UCI Cinemas and Finance Director of Sainsbury’s Supermarkets. His early career included finance roles with Shell and Hanson Plc.

Margaret joined the Board in August 2017. She is currently a Non-Executive Director and Chair of the Audit and Risk Committee of ITV plc and a Non-Executive Director of International Consolidated Airlines Group, S.A., where she is a member of the Audit and Compliance Committee and the Nominations Committee.

Margaret has held Non-Executive Director roles with Standard Chartered plc, Whitbread plc and the Confederation of British Industry and was also the Independent External member of the Audit Committee of the John Lewis Partnership. From 1987-1999, she was a corporate finance partner of Deloitte LLP and returned to the firm in 2007 as a Vice Chairman and latterly as Managing Partner, before retiring in 2012. Margaret was Group Chief Financial Officer of Trinity Mirror plc from 2000 – 2002 and Chief Financial Officer of BAA PLC from 2002 – 2006.

Constantin joined the Board as a Non-Executive Director in September 2020 and is an internationally recognised key opinion leader in the fields of biomedical engineering, image-guided therapy and drug delivery. Constantin holds a BA, MEng, MA and PhD degrees in Engineering from University of Cambridge and was appointed to the first Statutory Chair in Biomedical Engineering at the University of Oxford in 2011. He is currently the Director of the Institute of Biomedical Engineering at the University of Oxford, which is focused on the disciplines of non-invasive therapies, drug delivery, regenerative medicine, medical imaging, AI in healthcare, neurotechnology and biomaterials. Constantin is also Professor Fellow of Magdalen College and a Trustee of the Oxford Transplant Foundation.

Beyond his roles in academia, Constantin also has a proven track record of translating research into technology through entrepreneurship, recognised by the 2017 Silver Medal of the Royal Academy of Engineering. He is the founder and has been CTO/CSO of three successful spin-outs, OrganOx Limited, OxSonics Limited, and OrthoSon Limited, and now serves on each of their boards as a Non-Executive Director. Between 2014 and 2020, he direct and led the Oxford Centre for Drug Delivery Devices, a cross-disciplinary centre working across pharmaceutical and medical device companies and the NHS. In 2019, he was elected a Fellow of the Royal Academy of Engineering.

Brian joined the Board as a Non-Executive Director in March 2020. He is currently a Non-Executive Director of Ferguson Enterprises Inc., where Brian is also a member of its Nominations and Governance Committee and Audit Committee and a Non-Executive Director of OFI Group Limited, where he is also Chair of its Audit Committee.

Brian previously served as a Non-Executive Director of United Utilities Group PLC between September 2012 and July 2021. Brian was formerly Chief Financial Officer of Bunzl plc from 2006 to 2019 and, prior to that, he held a number of senior management finance roles with Bunzl, including divisional Finance Director, Group Treasurer and Head of Internal Audit. He qualified as a Chartered Accountant with KPMG in 1988.

Heather joined the Board as a Non-Executive Director in July 2020.  She is currently Chair of SCA Pharma, Non-Executive Director of Pendulum Therapeutics, Inc., Immatics N.V. and Assertio Holdings Inc. where Heather is also a member of the Audit Committee and Compliance Committee.

Heather spent 27 years with Abbott Laboratories where she held a number of global senior operational and strategic leadership roles, including Senior Vice President of Abbott Diabetes Care and most recently, Executive Vice President of Abbot Nutrition. Prior to joining Abbott, Heather worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Heather holds a B.S.E. in Industrial Engineering from the University of Michigan and an M.B.A. from the University of Chicago.

Kimberly joined the Board as a Non-Executive Director in February 2022. Kimberly's previous roles include; President and CEO of Sonida Senior Living Corporation, a US listed company; President of GN Hearing for North America and also served on GN Store Nord's global management team; as President of Chronic Care for the US subsidiary of Coloplast; as Chief Marketing Officer for Gentiva Health Services and as consultant for several private equity firms and portfolio companies. Kimberly is currently Chair of Nobi N.V., she also serves on several industry-related boards and committees and has previously held various other senior leadership roles.

Kimberly is highly skilled at business strategy, growth and transformation, with a strong record of leading companies to consistent outperformance and has extensive experience in healthcare products, services and delivery, including health insurance, durable medical equipment, infusion therapy, nursing and hospice, and medical devices.

Sharon joined the Board as a Non-Executive Director in March 2022 and is Convatec’s designated Non-Executive Director for workforce engagement. Sharon has over 40 years of healthcare and executive experience, with focus on driving quality, efficiency and innovation.

From 2011 to 2022, Sharon was President and Chief Operating Officer of UChicago Medicine, a US nationally ranked medical centre with a network of physicians and clinics with 10,000 employees and operating revenue in excess of $2 billion.

She is a Non-Executive Director of Adtalem Global Education, Apollo Endosurgery and Vocera Communications, a healthcare technology company. She was previously Non-Executive Director of Aviv REIT, a healthcare REIT. Sharon holds an M.S. in Nursing Administration from the Loyola University of Chicago, and a B.S in Nursing from the Northern Illinois University.

Jonny Mason was appointed Chief Executive Officer on 6 November 2025, following a period as Interim CEO since 4 August 2025. Jonny joined Convatec on 31 January 2022 and was appointed CFO from 12 March 2022 when he joined the Board of Directors. Jonny has played an instrumental role in leading the company’s pivot to sustainable and profitable growth and shaping its ongoing strategy.

An engineer and accountant by training, Jonny is a seasoned C-Suite leader with an extensive track record in listed and international businesses and brings diverse strategic enterprise transformation and operational leadership experience, combined with deep financial acumen and strong customer orientation.

A talented people-leader, he has made a significant contribution to Convatec’s turnaround and pivot to sustainable and profitable growth. He has a strong track record in publicly listed and international businesses, particularly those going through transformation, where he has built and led high performing teams, shaped engaging and impactful strategy, and delivered a stronger balance sheet with a sharp focus on cash and cost control.

Prior to joining Convatec, Jonny was Chief Financial Officer of Dixons Carphone Plc, now known as Currys Plc, between 2018-2021. Previous roles include CFO of Halfords Plc from 2015 and he was their interim Chief Executive Officer between September 2017 and January 2018. Jonny has built up a diverse and strong portfolio of experience, including being CFO of Scandi Standard AB, CFO at Odeon and UCI Cinemas and Finance Director of Sainsbury’s Supermarkets. His early career included finance roles with Shell and Hanson Plc.

Fiona Ryder was appointed Chief Financial Officer on 6 November 2025, following a period as Interim CFO since 4 August 2025. Fiona joined on 3 January 2022 as Group Financial Controller, and has played a fundamental role in delivering Convatec’s strategic focus on simplification and productivity, core to its FISBE strategy. Fiona has provided strong leadership for Convatec Tax, Treasury, Indirect Procurement, Finance Transformation and Data and Analytics strategy.

 
A senior finance leader with more than 25 years international and cross sector expertise, Fiona has worked in the US, Singapore and UK. After qualifying as an accountant with KPMG, she spent two decades at BP where she held roles including Chief of Staff to the Chief Financial Officer of their downstream business and spent a decade at the Castrol global lubricants business where she held a variety of commercial finance and performance roles, including as CFO of their Global Marine and Energy Business and CFO of Castrol Asia. Before joining Convatec, she was VP, Financial Accounting, Control and Reporting for all customer and products businesses, including Fuel and Retail, Advanced Mobility, Refining, Castrol and Air BP. She completed PwC’s CFO development programme in 2024.

David joined Convatec in November 2018. He was previously at Johnson and Johnson (J&J) for 26 years, where he held a variety of sales, marketing, strategic and operations roles. In his later roles, David spent 7 years as President of various J&J businesses, including US President for Cardiovascular and Specialty Services and Global President for Biosense Webster.

As President & Chief Operating Officer, Advanced Wound Care at Convatec until transitioning to his new role from 1 October 2025, David has been responsible for transforming our wound care business, with the industry’s most ambitious wound care solutions pipeline, focused on helping improve care for patients around the world. As Chief Commercial Officer, David will work across Convatec businesses to sharpen commercial execution, customer centricity and sharing best practice. He is responsible for Convatec’s Centres of Excellence for Global Marketing & Sales and Strategic Pricing.

David holds a Diploma in Marketing and a BSc in Management Science from the University of Lancaster.

Divakar joined Convatec in January 2020. Prior to joining he was Chief Digital Officer and Vice President for Eli Lilly’s Drug Delivery, Device and Digital Health groups, where he led a global R&D team focused on developing innovative and digitally-enabled devices to improve patient care. Divakar’s career in healthcare spans more than 20 years. During this time, in addition to working in product development, he has built strong expertise in process development. He served as Eli Lilly’s Vice President of Manufacturing Science and Technology, a role in which he oversaw all the company’s process development across its entire product portfolio.

Divakar holds a PhD in Chemical Engineering from Pennsylvania State University and a Bachelor of Technology degree in Chemical Engineering from Anna University in India. He also holds an MBA from Harvard Business School.

Tanja joined Convatec in January 2019 and has spent over 25 years in leadership roles across the medical technology, biopharma and pharmaceutical industry.

At Convatec, Tanja was Vice President, Advanced Wound Care – Europe until 2024, when she took on leadership for Convatec’s next generation adaptive platform, which brought to market our breakthrough nitric oxide wound dressing technology, ConvaNiox^TM, Tanja was promoted to the Convatec Executive Leadership Team as President & Chief Operating Officer, Advanced Wound Care in October 2025. 

Prior to Convatec, she held leadership roles with companies including Sandoz and Novartis, and previously served on the Board of HEXAL AG, a German pharmaceutical company, part of the Sandoz Group.

Tanja has a Bachelor’s degree in in Business Administration and Marketing from the University of Applied Sciences, Wuerzburgand, Germany and has also completed a range of executive education programmes including Harvard Business School’s Business Finance programme.

Bruno joined Convatec in August 2005 and has a diverse range of experience across Sales, Business Development & Global Emerging Markets. He was previously Head of our Latin America business before being promoted to an interim role of President & COO, Global Emerging Markets in September 2021. In May 2022 Bruno took over the position of President & Chief Operating Officer, Ostomy Care. From 2005-08, Bruno worked for Bristol Myers Squibb before its divestiture of Convatec in 2008.

In his former role, Bruno led a diverse team operating across eight countries and drove significant growth and expansion for the sub region. A key area of development has been the launch of seven Convatec Medical Care clinics throughout various countries in Latin America. Bruno was also responsible for achieving ‘Great Place to Work’ recognition for multiple markets within the region, demonstrating the importance of our values as an employer.

Bruno graduated with a Bachelor’s degree in Marketing & Advertising and a Master’s degree in Business Administration from Getúlio Vargas Business School, São Paulo, Brazil.

Mark joined Convatec in 2012 following the acquisition of 180 Medical – a leading home services medical devices company in the United States, offering high-quality catheters and ostomy products.

He has diverse experience across commercial, sales, marketing, customer loyalty programmes and operations. He joined 180 Medical in 2007 and has spent almost two decades in medical devices home services in roles – including as Director of Customer Services and Chief Operating Officer, including responsibility for home services technology – before his most recent role as Chief Commercial Officer, Home Services Group and VP, Head of Global Marketing – Continence Care, before being promoted to the Convatec Executive Leadership Team as President & Chief Operating Officer, Continence Care and Home Services Group in October 2024. Prior to joining Convatec he worked for several years in retail and logistics.

Mark leads a diverse team operating around the world and has driven significant growth within the Continence Care and Home Services Group business unit. A key area of leadership success has been Mark’s role in delivering world class customer Net Promotor Scores for 180 Medical and Amcare, and his leadership in accelerating customer loyalty more broadly across the business while also championing a range of culture and engagement programmes.

Mark completed Harvard Business School’s Advanced Management Programme in 2022 and has a Bachelor’s degree in Finance and Management from Oklahoma Baptist University.

Kjersti joined Convatec in January 2018 as President EMEA, and from February 2020, became President & Chief Operating Officer, Continence Care. In January 2022, she was appointed President & Chief Operating Officer, Infusion Care. Kjersti also has CELT-level responsibility for our Marketing Centre of Excellence.

Prior to Convatec, she was President Europe and the Middle East and President International, at Alere, Inc. Kjersti was a member of the founding team at Axis-Shield, which was acquired by Alere in 2011. Kjersti’s 25 years of experience in the medical technology sector includes over two decades in roles within diabetes care, including General Manager, Operations, Sales, Marketing and R&D positions.

Kjersti holds a Master of Science in Biotechnology from the Norwegian University of Science and Technology.

Anne Belcher joined Convatec on 18 April 2022 as President & Chief Operating Officer, Global Emerging Markets. 

Anne joined the business after 30 years at GlaxoSmithKline (GSK), where she most recently served as Senior Vice President & General Manager, Nordics. She originally joined GSK as a sales representative in New Zealand in 1991.

Anne has extensive experience in diverse market environments, including both mature and emerging markets across Asia Pacific, EMEA and the Americas. Her previous roles at GSK include SVP, Respiratory, Customer Capabilities and Operations, US (2019-2021); VP, General Manager in Australia (2016-2019); VP, Ethics and Compliance across Emerging Markets, Asia Pacific and Japan (2015-2016), General Manager of GSK’s Indonesian business (2011-15).

An outstanding people leader, she has built successful, compliant and effective teams that are results orientated, with a solid sales and commercial focus.

Originally from New Zealand, Anne is a pharmacist. Anne lives with her husband in Singapore.

Walter joined Convatec on 25 April 2022 as Head of Global Manufacturing, before being appointed to lead our Global Quality and Operations team in December 2025 on an interim basis.

A seasoned operations leader, bringing over 30 years’ experience in leading large and complex medical device operations to Convatec. Walter joined us from Hill-Rom, a global leader in medical technology, where he was most recently VP, Global Engineering Operations. Prior to Hill-Rom, Walter was VP, Global Manufacturing Operations at Haemonetics and was previously Director of Engineering at Covidien, as well as technical and operations roles at Gillette and P&G.

At Convatec, Walter has played a major role in delivering our global plant network optimisation, automation and standardisation programme, delivering significant efficiency benefits to the company and improvements for customers.

Walter holds a bachelor’s degree in Mechanical Design and Project Management, and an Executive MBA from Northeastern University, Boston. He is a US Army veteran where he served in the US Army 10^th Mountain Division for two years. Walter is based in Boston, US.  

Emma Rose joined Convatec on 8 April 2024. She was previously Chief Human Resources Officer at Travis Perkins plc, the UK’s largest distributor of building materials with more than 20,000 colleagues in the UK and Europe. Prior to this, Emma held senior HR roles at Kerry Foods, InterContinental Hotels Group and Mondelēz International.

She is a seasoned HR leader with over 20 years’ experience and a strong track record for delivering transformational people and culture strategies.

Emma is also a trustee and non-executive director of the Special Olympics Great Britain.

Evy joined Convatec in November 2020 as Chief of Corporate Strategy and Business Development and in April 2021 assumed the roles of General Counsel and Company Secretary. In May 2024, Evy’s role became EVP, Chief Strategy & Business Development Officer. Evy has deep expertise in the MedTech sector, having spent twenty years at Becton, Dickinson and Company prior to joining Convatec.  At BD, she was Senior Vice President of Corporate Development and Strategy and whilst there she helped the company build its capabilities around corporate development & strategy and assisted the global business units in strengthening their strategic focus and pursuing opportunities for partnerships, acquisitions and divestitures. Prior to her role in corporate development at BD, Evy held positions of increasing responsibility in the BD Law Group. She began her career at White & Case in New York.  

Evy holds a Juris Doctor Degree from Harvard Law School and a Bachelor’s with Honors in Political Science from Williams College, Massachusetts, U.S.

James Kerton joined Convatec on 7 May 2024, having previously been VP, Deputy General Counsel at Convatec between 2021-22. He leads Convatec’s global Legal, Intellectual Property, Ethics and Compliance, Data Privacy and Company Secretariat function.

James joined Convatec from Redde Northgate plc, where he was General Counsel and Company Secretary. James brings significant listed company and legal practice experience, having previously held senior legal roles at London Stock Exchange Group plc and Freshfields Bruckhaus Deringer LLP.

James is qualified as a solicitor in England and Wales, is a graduate of BPP Law School and holds an MA in History from the University of Cambridge.